Alto Neuroscience, Inc. (NYSE:ANRO) Financings

Alto Neuroscience, Inc.

Financings

RaiseDate
Registered direct offering of common stock
Announced: about US$100M · US$26.48 a share · BofA Securities +4
Dealers: BofA Securities (co-lead), Stifel (co-lead), William Blair (co-lead), Baird (co-lead), Jones
Buyers: EcoR1 Capital
Use of proceeds: Accelerate and expand clinical development of ALTO-207, including an additional Phase 3 trial in treatment-resistant depression, and working capital
Jul 13, 2026
Private placement of private placement financing (PIPE)
Closed: US$50M raised · US$5.914 a share
Buyers: Perceptive Advisors (Led the financing); Commodore Capital; Vestal Point Capital; Vivo Capital
Use of proceeds: To support the accelerated development of ALTO-207 following the successful FDA meeting
Nov 12, 2025

Read by 6ix AI from the company's releases